Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 AlteredExpression disease BEFREE During the last year the expression of anaplastic lymphoma kinase clarified presentation and provided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5) were mapped; constitutive activation of anaplastic lymphoma kinase by a chromosomal inversion was described; transformation was shown to be independent of nuclear localization of anaplastic lymphoma kinase; and phospholipase C-gamma was identified as a molecular target for the kinase activity of anaplastic lymphoma kinase. 10505771 1999
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE We present a case of anaplastic lymphoma kinase (ALK)+ skin-limited ALCL that highlights this challenge and draws attention to pitfalls in assessing ALK status. 25404214 2015
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. 28112990 2017
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Most ALK positive cases of ALCL harbor the t(2;5) translocation that leads to expression of Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK). 25961698 2015
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE We evaluated the incidence of ALCL, clinical characteristics, survival status, and outcome of crizotinib use in four relapsed/refractory ALK-positive patients. 29150811 2018
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE ALCL-negative tumours had a significantly worse prognosis than ALK-positive. 18275429 2008
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Difficulties with classification of lymphomas are also encountered, such as the distinction of classical Hodgkin's lymphoma from anaplastic large-cell lymphoma that is negative for anaplastic lymphoma kinase. 20227918 2010
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30<sup>+</sup>/ALK<sup>+</sup> anaplastic large cell lymphoma (ALCL). 30742941 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Our findings suggest that overexpression of c-FLIP protects ALK+ ALCL cells from death-receptor-induced apoptosis and may contribute to ALCL pathogenesis. 16304056 2006
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 AlteredExpression disease BEFREE Systemic anaplastic large-cell lymphoma (ALCL) is a childhood T cell neoplasm defined by the presence or absence of translocations that lead to the ectopic expression of anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK (NPM-ALK) fusions being the most common. 29581862 2018
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 AlteredExpression disease BEFREE ALK expression was detected in 60% of ALCLs, of which 79% exhibited the presence of NPM-ALK, whereas the remaining 21% expressed variant-ALK fusions. 24112608 2013
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE These findings may have clinical implications in the pathogenesis and prognosis of ALK-positive ALCLs. 15208656 2004
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 AlteredExpression disease BEFREE Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. 16254137 2006
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Systemic ALK+ ALCLs have improved prognosis compared with ALK-negative ALCL, although both subtypes warrant treatment with polychemotherapy. 20669794 2010
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 GeneticVariation disease BEFREE Anaplastic large cell lymphoma (ALCL) is a subtype of aggressive non-Hodgkin's lymphoma that is characterized by expression of CD30 and the NPM/ALK chimeric protein, which is generated by t(2;5)(p23;q35). 16533741 2005
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE To unravel signaling pathways required for NPM-ALK-mediated transformation and tumor maintenance, we analyzed the transcriptomes of ALK positive ALCL cell lines through experimentally controlled approaches in which ALK signaling was abrogated by an inducible ALKshRNA or by ALK inhibitors. 17695725 2007
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 GeneticVariation disease BEFREE The NPM/ALK fusion gene, formed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hybrid protein that containsthe amino-terminal portion of the nucleolar phosphoprotein nucleophosmin(NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). 11522649 2001
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Anaplastic lymphoma kinase (ALK) is frequently observed in systemic anaplastic large cell lymphoma (ALCL), mostly in childhood or adolescence, but only rarely in primary cutaneous cases. 15214912 2004
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Moreover, ALK expression was confined to the cytoplasm of the tumor cells in each case, supporting the hypothesis that the observed nuclear localization of NPM-ALK in classical ALCL is not the site of oncogenic activity of the ALK kinase. 10381534 1999
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Here, we identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. 21575866 2011
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Our study, which to our knowledge includes the largest series of childhood systemic ALK-positive ALCL so far, demonstrates the adverse prognostic value of SC and/or LH morphologic features. 22084369 2011
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Finally, we highlighted an inverse correlation between the levels of miR-16 and VEGF in human NPM-ALK+ Anaplastic Large Cell Lymphomas (ALCL). 21778999 2011
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE NPM-ALK is rarely, if ever, detected in Hodgkin's disease or secondary ALCL. 9684923 1998
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL). 29035291 2017
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Furthermore co-expression of NK and ALCL features supports the concept that a minority of null-ALCL may be derived from NK cells and expands the spectrum of phenotypes that can be seen in tumors produced by ALK fusion proteins.(Blood.2001;98:1209-1216) 11493472 2001